R&D COVID-19: Celltrion's therapeutic option In just over a year, Celltrion Healthcare says it has identified and delivered a potential treatment for COVID-19.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
